“The REVIVED trial was negative mainly because the medical therapy was a lot more superior, including MRA, Entresto, and the greater use of ICD in that trial.” said Dr. Sripal Bangalore in a conversation with Dr Vivudh Pratap Singh at the annual India Live 2024.
Here are the top 5 takeaways from their conversation:
1. REVIVED Trial Was Negative Due to Superior Medical Therapy, Including MRA, Entresto, and ICD.
2. CABG Is Crucial for Certain Patients, but Medical Therapy May Be More Effective.
3. Significant Progress in Medical Therapies Highlights Their Importance in Trials.
4. Advances in Medical Therapy Lead to Significant Improvements in Heart Failure and Ischemic Heart Disease.
5. Individualized Treatment Is Key, Balancing Medical Therapy with Interventions Like CABG.
Dr. Sripal Bangalore:
Dr. Sripal Bangalore is a renowned cardiologist and a leading expert in cardiovascular medicine. He is currently serving as a professor of medicine and the Director of the Cardiac Catheterization Laboratory at NYU Langone Health. He is the principal investigator of the ISCHEMIA-CKD trial, which focuses on determining the optimal management strategies for patients with chronic kidney disease (CKD) and stable ischemic heart disease (SIHD).
With extensive experience in the field, Dr. Bangalore has contributed significantly to the advancement of heart disease treatment, particularly in the areas of coronary artery disease and heart failure.
Dr. Bangalore has published over 400 articles in leading medical journals and has received numerous awards for his contributions to cardiology, including the Dr. Gregory Braden Memorial Fellow of the Year Award and the Douglas P. Zipes Distinguished Young Scientist Award.
Linkedin: https://www.linkedin.com/in/sripal-bangalore-999a3689/
Website: https://scai.org/sripal-bangalore-md-mha-fscai
Dr. Vivudh Pratap Singh:
Dr. Vivudh Pratap Singh, an alumnus of King George Medical College. He is currently serving as the Senior Consultant of Cardiology at Fortis Escorts Heart Institute. He has over 21 years of experience in the field of cardiology and is recognized for his expertise in interventional cardiology.
He is an accomplished interventional cardiologist recognized with the Professor N.N. Gupta and Professor S.M. Goswami gold medals for academic excellence.
Trained in CHIP, OCT, IVUS, rotablation, and complex angioplasties, he has also contributed to TAVI and EVAR programs and holds expertise in endovascular therapy, having trained at HML Paris. A recipient of the TCT-IABP Scholarship and an international conference faculty member, he is dedicated to providing compassionate, comprehensive care to the community. His clinical excellence and commitment to advanced techniques make him a leader in his field.
LinkedIn: https://www.linkedin.com/in/vivudh-pratap-singh-90323514a/
Website Profile: https://www.fortishealthcare.com/doctors/dr-vivudh-pratap-singh-1603
0:00 India Live Starting Montage
1:32 Introduction
1:56 When to Consider Revascularization in Ischemic Cardiomyopathy
3:27 REVIVED Trial Overview
4:19 Why the REVIVED Trial Was Negative
5:28 Indications for PCI in Clinical Practice
6:15 Challenges with Small Trial Sizes
6:56 The Future of PCI and Medical Therapy Trials
8:04 Conclusion and Future Research Directions
8:17 India Live Ending Montage
9:45 Disclaimer
#DrVivudhPratapSingh #DrSripalBangalore #FortisEscortsHeart Institute #NYU #LangoneHealth #IschemicCardiomyopathy #PCIcontroversy #TheRightDoctors #TRD
India's leading Medical Knowledge platform, TheRightDoctors, is a Google Launchpad Digital Health StartUp. We bring Insights from the World's Best Medical Minds to audiences worldwide.
Our recognitions:
Google Launchpad (USD200,000 in platform credit over two tranches), Berlin Bootcamp, Startup Networkz Singapore (Start-Up of Substance), and NASSCOM Showcase Start-Up.
Subscribe for more videos: https://bit.ly/2X2gQmF
Our Social Media Links:
Facebook - https://goo.gl/YO1oel
Twitter - https://goo.gl/J1gtvw
LinkedIn - https://bit.ly/368sfGb
Web - https://bit.ly/36qI3ma
#TheRightDoctors #TRD
© TheRightDoctors Knowledge Network. All rights reserved.
Here are the top 5 takeaways from their conversation:
1. REVIVED Trial Was Negative Due to Superior Medical Therapy, Including MRA, Entresto, and ICD.
2. CABG Is Crucial for Certain Patients, but Medical Therapy May Be More Effective.
3. Significant Progress in Medical Therapies Highlights Their Importance in Trials.
4. Advances in Medical Therapy Lead to Significant Improvements in Heart Failure and Ischemic Heart Disease.
5. Individualized Treatment Is Key, Balancing Medical Therapy with Interventions Like CABG.
Dr. Sripal Bangalore:
Dr. Sripal Bangalore is a renowned cardiologist and a leading expert in cardiovascular medicine. He is currently serving as a professor of medicine and the Director of the Cardiac Catheterization Laboratory at NYU Langone Health. He is the principal investigator of the ISCHEMIA-CKD trial, which focuses on determining the optimal management strategies for patients with chronic kidney disease (CKD) and stable ischemic heart disease (SIHD).
With extensive experience in the field, Dr. Bangalore has contributed significantly to the advancement of heart disease treatment, particularly in the areas of coronary artery disease and heart failure.
Dr. Bangalore has published over 400 articles in leading medical journals and has received numerous awards for his contributions to cardiology, including the Dr. Gregory Braden Memorial Fellow of the Year Award and the Douglas P. Zipes Distinguished Young Scientist Award.
Linkedin: https://www.linkedin.com/in/sripal-bangalore-999a3689/
Website: https://scai.org/sripal-bangalore-md-mha-fscai
Dr. Vivudh Pratap Singh:
Dr. Vivudh Pratap Singh, an alumnus of King George Medical College. He is currently serving as the Senior Consultant of Cardiology at Fortis Escorts Heart Institute. He has over 21 years of experience in the field of cardiology and is recognized for his expertise in interventional cardiology.
He is an accomplished interventional cardiologist recognized with the Professor N.N. Gupta and Professor S.M. Goswami gold medals for academic excellence.
Trained in CHIP, OCT, IVUS, rotablation, and complex angioplasties, he has also contributed to TAVI and EVAR programs and holds expertise in endovascular therapy, having trained at HML Paris. A recipient of the TCT-IABP Scholarship and an international conference faculty member, he is dedicated to providing compassionate, comprehensive care to the community. His clinical excellence and commitment to advanced techniques make him a leader in his field.
LinkedIn: https://www.linkedin.com/in/vivudh-pratap-singh-90323514a/
Website Profile: https://www.fortishealthcare.com/doctors/dr-vivudh-pratap-singh-1603
0:00 India Live Starting Montage
1:32 Introduction
1:56 When to Consider Revascularization in Ischemic Cardiomyopathy
3:27 REVIVED Trial Overview
4:19 Why the REVIVED Trial Was Negative
5:28 Indications for PCI in Clinical Practice
6:15 Challenges with Small Trial Sizes
6:56 The Future of PCI and Medical Therapy Trials
8:04 Conclusion and Future Research Directions
8:17 India Live Ending Montage
9:45 Disclaimer
#DrVivudhPratapSingh #DrSripalBangalore #FortisEscortsHeart Institute #NYU #LangoneHealth #IschemicCardiomyopathy #PCIcontroversy #TheRightDoctors #TRD
India's leading Medical Knowledge platform, TheRightDoctors, is a Google Launchpad Digital Health StartUp. We bring Insights from the World's Best Medical Minds to audiences worldwide.
Our recognitions:
Google Launchpad (USD200,000 in platform credit over two tranches), Berlin Bootcamp, Startup Networkz Singapore (Start-Up of Substance), and NASSCOM Showcase Start-Up.
Subscribe for more videos: https://bit.ly/2X2gQmF
Our Social Media Links:
Facebook - https://goo.gl/YO1oel
Twitter - https://goo.gl/J1gtvw
LinkedIn - https://bit.ly/368sfGb
Web - https://bit.ly/36qI3ma
#TheRightDoctors #TRD
© TheRightDoctors Knowledge Network. All rights reserved.
- Category
- Cardiology

Be the first to comment